SinoMab BioScience Limited Schedules Board Meeting to Approve 2025 Final Results

Hong Kong, 10 March 2026 — SinoMab BioScience Limited (Stock Code: 3681), a leading biopharmaceutical company listed on the Hong Kong Stock Exchange, has announced that its Board of Directors will hold a key meeting on Monday, 23 March 2026. The primary agenda will be to consider and approve the final results of the Group for the year ended 31 December 2025.

Key Points for Investors

• Date of Board Meeting: 23 March 2026
• Main Agenda: Approval of the final annual results for the financial year ended 31 December 2025
• Implications: The approval and publication of annual financial results are significant events that often lead to share price movements, as they provide an update on the company’s performance and outlook.
• Other Business: The Board may also transact any other business deemed necessary at the meeting.

Details for Shareholders

• The final results announcement is a key price-sensitive event. Investors and shareholders should closely monitor the outcome of the meeting, as the financial performance and any guidance or commentary provided by the Board could impact market sentiment and share value.
• The Board consists of a mix of executive, non-executive, and independent non-executive directors, including leading figures such as Dr. Shui On Leung (Executive Director, Chairman, and CEO), Dr. Haigang Chen, Mr. Xun Dong, Ms. Xiaosu Wang, Dr. Jianmin Zhang, Mr. George William Hunter Cautherley, Mr. Ping Cho Terence Hon, Dr. Chi Ming Lee, Ms. Chi Sau Giselle Lee, and Mr. Nan Shen.
• The official results will be published following the meeting, providing critical insights into the Group’s operational and financial performance over the past year.

Potential Price Sensitivity

The upcoming Board meeting and subsequent results announcement represent a potentially price-sensitive event for SinoMab BioScience Limited. The final results will reveal the company’s financial health, R&D progress, and business outlook, all of which are key determinants for share valuation. Investors should be aware that stock prices often react to such disclosures, especially if results exceed or fall short of market expectations or if significant strategic updates are provided.

Conclusion

Shareholders and investors are advised to stay alert for the official publication of SinoMab’s annual results following the 23 March 2026 Board meeting. The disclosed financials and any accompanying statements from management could have a direct impact on the company’s share price in the near term.

Disclaimer: The above article is based on a public announcement by SinoMab BioScience Limited. This report is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a licensed financial advisor before making any investment decisions. The author and publisher accept no liability for any loss arising from reliance on this information.

View SINOMAB BIO-B Historical chart here